ARTICLE | Emerging Company Profile
LUCA: off-the-shelf mitochondria for wide-ranging applications
Tokyo-based LUCA believes mitochondrial transplant can restore function after heart attack, treat rare diseases, enhance cell therapies and more
June 7, 2022 5:56 PM UTC
With a fresh $30.3 million from an oversubscribed series B financing, Tokyo-based LUCA is optimizing its mitochondrial isolation technology to deliver allogeneic mitochondria for restoring energy production in dysfunctional or damaged cells.
LUCA believes its single off-the-shelf product offers a pipeline of opportunities, which it is exploring through both an internal pipeline and several partnerships...